These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26730808)

  • 1. A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands.
    Boichenko I; Deiss S; Bär K; Hartmann MD; Hernandez Alvarez B
    J Med Chem; 2016 Jan; 59(2):770-4. PubMed ID: 26730808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of BODIPY FL Thalidomide As a High-Affinity Fluorescent Probe for Cereblon in a Time-Resolved Fluorescence Resonance Energy Transfer Assay.
    Lin W; Li Y; Min J; Liu J; Yang L; Lee RE; Chen T
    Bioconjug Chem; 2020 Nov; 31(11):2564-2575. PubMed ID: 33070611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase.
    Matyskiela ME; Lu G; Ito T; Pagarigan B; Lu CC; Miller K; Fang W; Wang NY; Nguyen D; Houston J; Carmel G; Tran T; Riley M; Nosaka L; Lander GC; Gaidarova S; Xu S; Ruchelman AL; Handa H; Carmichael J; Daniel TO; Cathers BE; Lopez-Girona A; Chamberlain PP
    Nature; 2016 Jul; 535(7611):252-7. PubMed ID: 27338790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate.
    Matyskiela ME; Couto S; Zheng X; Lu G; Hui J; Stamp K; Drew C; Ren Y; Wang M; Carpenter A; Lee CW; Clayton T; Fang W; Lu CC; Riley M; Abdubek P; Blease K; Hartke J; Kumar G; Vessey R; Rolfe M; Hamann LG; Chamberlain PP
    Nat Chem Biol; 2018 Oct; 14(10):981-987. PubMed ID: 30190590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.
    Matyskiela ME; Zhang W; Man HW; Muller G; Khambatta G; Baculi F; Hickman M; LeBrun L; Pagarigan B; Carmel G; Lu CC; Lu G; Riley M; Satoh Y; Schafer P; Daniel TO; Carmichael J; Cathers BE; Chamberlain PP
    J Med Chem; 2018 Jan; 61(2):535-542. PubMed ID: 28425720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cereblon modulators: Low molecular weight inducers of protein degradation.
    Chamberlain PP; Cathers BE
    Drug Discov Today Technol; 2019 Apr; 31():29-34. PubMed ID: 31200856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PROTAC-mediated crosstalk between E3 ligases.
    Steinebach C; Kehm H; Lindner S; Vu LP; Köpff S; López Mármol Á; Weiler C; Wagner KG; Reichenzeller M; Krönke J; Gütschow M
    Chem Commun (Camb); 2019 Feb; 55(12):1821-1824. PubMed ID: 30672516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Midori-ishi Cyan/monomeric Kusabira-Orange-based fluorescence resonance energy transfer assay for characterization of various E3 ligases.
    Otsubo R; Kim M; Lee J; Sasakawa C
    Genes Cells; 2016 Jun; 21(6):608-23. PubMed ID: 27091465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective nonpeptidic fluorescent ligands for oxytocin receptor: design, synthesis, and application to time-resolved FRET binding assay.
    Karpenko IA; Margathe JF; Rodriguez T; Pflimlin E; Dupuis E; Hibert M; Durroux T; Bonnet D
    J Med Chem; 2015 Mar; 58(5):2547-52. PubMed ID: 25642985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic Imaging of Small Molecule Induced Protein-Protein Interactions in Living Cells with a Fluorophore Phase Transition Based Approach.
    Chung CI; Zhang Q; Shu X
    Anal Chem; 2018 Dec; 90(24):14287-14293. PubMed ID: 30431263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical Ligand Space of Cereblon.
    Boichenko I; Bär K; Deiss S; Heim C; Albrecht R; Lupas AN; Hernandez Alvarez B; Hartmann MD
    ACS Omega; 2018 Sep; 3(9):11163-11171. PubMed ID: 31459225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive selection of cereblon modified function including its E3 ubiquitin ligase activity and binding efficiency with AMPK.
    Onodera W; Asahi T; Sawamura N
    Mol Phylogenet Evol; 2019 Jun; 135():78-85. PubMed ID: 30836149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and characterization of potent spiro-isoxazole-based cereblon ligands with a novel binding mode.
    Shevalev R; Bischof L; Sapegin A; Bunev A; Olga G; Kantin G; Kalinin S; Hartmann MD
    Eur J Med Chem; 2024 Apr; 270():116328. PubMed ID: 38552426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In pursuit of synthetic modulators for the orphan retina-specific nuclear receptor NR2E3.
    Qin Q; Knapinska A; Dobri N; Madoux F; Chase P; Hodder P; Petrukhin K
    J Ocul Pharmacol Ther; 2013 Apr; 29(3):298-309. PubMed ID: 23098562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs.
    Ito T; Handa H
    Int J Hematol; 2016 Sep; 104(3):293-9. PubMed ID: 27460676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recent topics in IMiDs and cereblon].
    Ito T; Handa H
    Rinsho Ketsueki; 2017; 58(10):2067-2073. PubMed ID: 28978850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deciphering the mystery of thalidomide teratogenicity.
    Ito T; Handa H
    Congenit Anom (Kyoto); 2012 Mar; 52(1):1-7. PubMed ID: 22348778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of targeted protein degradation therapeutics.
    Chamberlain PP; Hamann LG
    Nat Chem Biol; 2019 Oct; 15(10):937-944. PubMed ID: 31527835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a primary target of thalidomide teratogenicity.
    Ito T; Ando H; Suzuki T; Ogura T; Hotta K; Imamura Y; Yamaguchi Y; Handa H
    Science; 2010 Mar; 327(5971):1345-50. PubMed ID: 20223979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for protein kinase C ligands using fluorescence resonance energy transfer.
    Ohashi N; Nomura W; Minato N; Tamamura H
    Chem Pharm Bull (Tokyo); 2014; 62(10):1019-25. PubMed ID: 25109829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.